Unlock this StockReport nowClick to Unlock

Hvivo Share Price

HVO 19.51p -0.5  -2.4%
9:52am 10.00k

Relative Strength (%)
Volume Change (%)
10d v 3m
Price vs... (%)
52w High
50d MA
200d MA
Growth & Value
Margin of Safety (beta)
Screens Passed
Balance Sheet · Income Statement · Cashflow Financial Summary
Year End 31st Dec 2013 2014 2015 2016 2017 2018 2019E 2020E CAGR / Avg
Revenue £m
Operating Profit £m
Net Profit £m
EPS Reported p
EPS Normalised p
EPS Growth %
PE Ratio x
Operating Margin %
Op. Cashflow ps p
Capex ps p
Free Cashflow ps p
Dividend ps p
Dividend Growth %
Dividend Yield %
Dividend Cover x
Balance Sheet
Cash etc £m
Working Capital £m
Net Fixed Assets £m
Net Debt £m
Book Value £m
Average Shares m
Book Value ps p -23.1%

FINANCIAL BRIEF: For the fiscal year ended 31 December 2018, Hvivo PLC revenues increased 1% to £11M. Net loss increased 31% to £16.8M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Finance income decrease of 18% to £58K (income). Basic Earnings per Share excluding Extraordinary Items decreased from -£0.16 to -£0.21. more »

Health Trend
Bankruptcy Risk
  Earnings Manipulation Risk
Magic Formula Score  
Other Ratios
Leverage (ttm) Total -Intang +Pension
Gross Gearing %
Net Gearing %
Cash / Assets %
Recent History
Latest interim period (ended 31st Dec '18) vs. prior year
Sales Growth %
EPS Growth %
3yr Compound Annual Growth Rate
Sales Growth %
EPS Growth %
DPS Growth %

Broker Forecasts
31st Dec 2019
31st Dec 2020

Price Target: 1.00
(+4001% above Price)
Net Profit EPS DPS Net Profit EPS DPS
Est. Long Term Growth Rate: n/a (£) (p) (p) (£) (p) (p)
Consensus Estimate
1m Change
3m Change
1 broker Broker Consensus Trend
Broker Recommendations for Hvivo
Recommendation:Strong SellSellHoldBuyStrong Buy
No. of Analysts: 0 0 0 0 1

Named Brokers and Analysts
Numis Securities Paul Cuddon ,

Profile Summary

hVIVO plc, formerly Retroscreen Virology Group plc, is a holding company. The Company is engaged in a life sciences business pioneering a technology platform of human disease models to accelerate drug discovery and development in respiratory and infectious diseases, including flu, respiratory syncytial virus (RSV), asthma and common cold. It has commercialized approximately four disease models, enrolled over 2,000 subjects and conducted approximately 40 product validation studies for a range of industry, government and academic clients and collaborators. The Company offers services, such as challenge study services, lab services, and target and biomarker discovery. It offers viral challenge studies in healthy volunteers in influenza, human rhinovirus (HRV) and RSV. Its lab services include assay development, transfer and optimization across the immunological, molecular and cell-based assay platforms, including offering options in sample matrix testing and specialty biomarker assays.

Directors: Trevor Phillips (CHM) 56, Anesh Patel (FID) , Trevor Nicholls (NED) 61, Mark Warne (NED) , James Winschel (NED) 66,

No. of Employees: 139 No. of Shareholders: n/a

Last Annual December 31st, 2018
Last Interim December 31st, 2018
Incorporated March 27, 2012
Public Since May 3, 2012
Shares in Issue 83,120,420
Free Float 78.6m (94.6%)
Sector Healthcare
Industry Healthcare Providers & Services
Exchange London Stock Exchange (AIM)
Eligible for an ISA? a SIPP?

HVO Share Price Performance HVO Share Price Quote
-0.5  -2.4%
Traded 9:52am · Minimum 15 min delayed · NMS: 10.00k

Latest HVO News Announcements (delayed)

Upcoming HVO Events

Recent ↓
Thursday 30th May, 2019
Hvivo PLC Annual Shareholders Meeting
Thursday 11th April, 2019
Full Year 2018 Hvivo PLC Earnings Release
Thursday 11th April, 2019
Full Year 2018 Hvivo PLC Earnings Call
Thursday 16th August, 2018
Half Year 2018 Hvivo PLC Earnings Release
Thursday 16th August, 2018
Half Year 2018 Hvivo PLC Earnings Call
Friday 20th April, 2018 (estimate)
Full Year 2017 Hvivo PLC Earnings Release
Thursday 21st September, 2017
Half Year 2017 Hvivo PLC Earnings Release
Thursday 20th April, 2017
Full Year 2016 Hvivo PLC Earnings Release
Thursday 22nd September, 2016
Half Year 2016 Hvivo PLC Earnings Release
Wednesday 10th August, 2016
Hvivo PLC at Canaccord Genuity Growth Conference
Tuesday 1st September, 2015 (estimate)
Retroscreen Virology Group PLC Annual Shareholders Meeting
Monday 1st September, 2014
Retroscreen Virology Group PLC Annual Shareholders Meeting

Use of our data service is subject to express Terms of Service. Please see our full site disclaimer for more details. In particular, it is very important to do your own research (DYOR) and seek professional advice before making any investment based on your own personal circumstances. Please note that the information, data and analysis contained within this stock report: (a) include the proprietary information of Stockopedia's third party licensors and Stockopedia; (b) should not be copied or redistributed except as specifically authorised; and (c) are not warranted to be complete, accurate or timely. You should independently research and verify any information that you find in this report. Stockopedia will not be liable in respect of any loss, trading or otherwise, that you may suffer arising out of such information or any reliance you may place upon it. Past performance is no guarantee of future results. The value and income derived from investments may go down as well as up. © Stockopedia 2019.

Should you buy HVO

Access HVO Analytics Now!

Let’s get you setup so you get the most out of our service
Done, Let's add some stocks
Brilliant - You've created a folio! Now let's add some stocks to it.

  • Apple (AAPL)

  • Shell (RDSA)

  • Twitter (TWTR)

  • Volkswagon AG (VOK)

  • McDonalds (MCD)

  • Vodafone (VOD)

  • Barratt Homes (BDEV)

  • Microsoft (MSFT)

  • Tesco (TSCO)
Save and show me my analysis